Fig. 6: Antibodies against IFN-γ and TNF-α blocked the differentiation of tumors, an increased effect was seen in primary NK differentiated tumors compared sNK differentiated tumors.

Differentiation of OSCSCs (A) and MP2 (B) was conducted as described in Fig. 4. Primary IL-2 and anti-CD16 mAbs-treated and sNK cells’ supernatant-treated tumors were a combination of anti-TNFα mAbs (1:100) and anti-IFNγ mAbs (1:100) for six days. Freshly purified NK cells were treated with IL-2 (1000 U/mL) for 18 h and were used as effectors against untreated tumors, and primary IL-2 and anti-CD16 mAbs-treated, and sNK cells’ supernatant-treated tumors in the absence or presence of anti-TNFα mAbs and anti-IFNγ mAbs to measure NK cell-mediated cytotoxicity using a standard 4-h ⁵¹Cr release assay against tumor cells. The lytic units (LU) 30/10⁶ cells were determined using the inverse number of NK cells required to lyse 30% of target cells × 100 (A, B).